Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.57 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16232160 | 0.80 | HSD11B1 (0.83) | HSD11B1SLC6A3MEN1KMT2A | |
| SCHEMBL17761233 | 0.79 | HSD11B1 (0.60) | HSD11B1SLC6A3SLC6A4SLC6A2MEN1 | |
| SCHEMBL16232162 | 0.79 | HSD11B1 (0.60) | HSD11B1SLC6A3SLC6A4SLC6A2MEN1 | |
| SCHEMBL1635382 | 0.78 | PSEN1 (0.39) | HSD11B1PLOD2 | |
| Trifluoroacetic Acid SCHEMBL30676275 | 0.74 | HSD11B1 (0.48) | HSD11B1PLOD2SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL627571 | 0.74 | HSD11B1 (0.90) | HSD11B1SLC6A3SLC6A4SLC6A2MEN1 | |
| SCHEMBL4245329 | 0.74 | HSD11B1 (0.97) | HSD11B1SLC6A3SLC6A4SLC6A2MEN1 | |
| SCHEMBL17761217 | 0.72 | HSD11B1 (0.66) | HSD11B1SLC6A3SLC6A4SLC6A2MEN1 | |
| SCHEMBL17761311 | 0.72 | HSD11B1 (0.71) | HSD11B1SLC6A3SLC6A4SLC6A2CACNA1G | |
| SCHEMBL1633723 | 0.72 | HTR2A (0.42) | KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8212040-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-7932392-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7553966-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1490062-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMA (US) | 2007-12-19 | — | — | EP | disclosed |
| US-7268152-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20060189647-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20050282881-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| US-6903215-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20050059714-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| EP-1490317-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1490062-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040029932-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-02-12 | — | — | US | disclosed |
| US-20040023999-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003082280-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082787-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189647-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof | NR3C1, NR3C2, MC2R | HSD11B1 17/4885PLOD2 4551/4885SLC6A3 4066/4885 |
| US-20040029932-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | HSD11B1 9/4885PLOD2 4371/4885SLC6A3 4394/4885 |
| US-20050059714-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | HSD11B1 21/4885PLOD2 4657/4885SLC6A3 4149/4885 |
| US-20040023999-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | HSD11B1 9/4885PLOD2 4371/4885SLC6A3 4394/4885 |
| US-20050282881-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | HSD11B1 27/4885PLOD2 4398/4885SLC6A3 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.